Achieve Life Sciences Preps for Q1 2026 Earnings Amid FDA Review Timeline
Event summary
- Achieve Life Sciences will report Q1 2026 financial results on May 12, 2026.
- FDA review of cytisinicline NDA continues with PDUFA date set for June 20, 2026.
- Company has completed Phase 3 studies for smoking cessation and Phase 2 for vaping.
- FDA awarded Breakthrough Therapy designation for vaping cessation indication.
- Cytisinicline targets 25M U.S. smokers and 18M e-cigarette users.
The big picture
Achieve Life Sciences is navigating a critical regulatory phase with its cytisinicline NDA under FDA review. The company is positioning itself in a $10B+ global smoking cessation market, with potential expansion into vaping cessation. Success hinges on FDA approval and effective commercialization strategy.
What we're watching
- Regulatory Approval
- Whether the FDA will approve cytisinicline by the June 20 PDUFA date.
- Market Potential
- The pace at which Achieve can commercialize cytisinicline if approved.
- Competitive Positioning
- How Achieve differentiates cytisinicline in the smoking cessation market.
Related topics